(571) 447-5500

Product Development and Labeling

EAS’s strategic consulting service will provide solutions to companies confronting daunting product development and labeling issues by taking a holistic approach that considers a company’s marketing objectives and the current regulatory, compliance, and enforcement environment at the federal, state and local levels. The service is most often provided by a small team of expert consultants with complementary backgrounds.

Clients are guided through the various regulatory processes at each level of government including government affairs strategies, how to best effectuate policy changes and file official comments as necessary.

Our consultants help address questions such as: Should your company disclose GMO ingredients, create a “non-GMO” product line, or stay the course? What are the risks of self-defining “natural” foods including the risk of class action litigation challenging such claims? How can your company make undefined claims such as “Handcrafted” while minimizing risk from federal and state regulatory authorities and more?

Let EAS help develop proactive solutions for:

GMO Labeling

“Natural” Foods and Claims

Undefined Claims

New Threats Posed by FDA Warning Letters


Trending Claims

Nutrition Labeling

Competitive Challenges

Crisis Management

Long-Term Planning

Submissions Assistance

In-House Training

Related News

Food Labeling Challenges in a Pandemic

Under normal circumstances, food producers have many plates to spin in order to comply with food regulations, including food labeling requirements. Most especially, in order to assure accurate food ingredient, allergen and nutrition labeling, manufacturers must be certain they possess the most recent …

Personal Care and Healthy Aging

As the overall population of the U.S. continues to gain longevity, consumers demand personal care products that address the signs and symptoms of aging. Everyone gets older, but no one wants to feel or look older.

Consumers are willing to pay a …

Drug and Device Corner for May 2020

FDA anticipates that during a pandemic, industry and FDA workforces may be reduced because of high employee absenteeism while reporting of adverse events related to widespread use of medical products indicated for the treatment or prevention of the pathogen causing the pandemic may increase. The extent …

Got a Question?

Contact Us Today for a Complimentary Consultation!